After H.C. Wainwright and Chardan Capital gave BiomX (NYSE MKT: PHGE) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on BiomX today and set a price target of $25.00. The company’s shares closed last Thursday at $6.40.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 11.8% and a 36.0% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Rhythm Pharmaceuticals.
BiomX has an analyst consensus of Strong Buy, with a price target consensus of $22.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.05 and a one-year low of $4.55. Currently, BiomX has an average volume of 61.86K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
